Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $21.59M (cash outflow) rose 131.9% year over year, behind the +152.1% change in trailing-twelve-month net income. Sequentially, it rose 22.7% from the prior quarter. Over 3 fiscal years it compounded at +61.9% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$83.24M (+44.5%) for the fiscal year ending Dec 2026, a slowdown from the +179.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.59M+22.7% QoQ
- Last fiscal yearDec 2025
- -$57.59M+179.7% YoY
- LTMMar 2026
- -$69.87M+152.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +131.9% | +30.3% | -101.5 pp |
| 1 year | +179.7% | +44.5% | -135.2 pp |
| 3-year CAGR | +61.9% | +8.4% | -53.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (57.59M) USD
- Year-over-year change
- -179.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.59M) | -179.7% |
| FY2024 | 2024-12-31 | (20.59M) | -185.6% |
| FY2023 | 2023-12-31 | (7.21M) | +46.9% |
| FY2022 | 2022-12-31 | (13.56M) | — |
Net Income vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 net income of $69.87M is the 7th largest of the 11 companies compared; the peer median is $76.38M.
- Its year-over-year change of +152.1% is the highest of 11, against a peer median of -15.5%.
- Over three fiscal years its annual growth of +61.9% compares with a peer median of -4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $133.22M | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $84.74M | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $83.01M | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $69.87M | +152.1% | +61.9% | — | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $42.72M | +84.6% | +27.3% | — |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding AARD) | $76.38M | -15.5% | -4.6% | 589.8% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.